Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NSE India Stock Exchange  >  HDFC Bank Limited    HDFCBANK   INE040A01034

HDFC BANK LIMITED

(HDFCBANK)
  Report
End-of-day quote. End-of-day quote NSE India Stock Exchange - 11/26
1426.65 INR   +1.70%
05:39aIndian shares jump as metals, financials gain
RE
11/23HDFC BANK : Disclosure under Reg. 30 of SEBI LODR
PU
11/16HDFC BANK : Schedule of analyst and investor meet
PU
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Indian shares end lower as banks drop; pharma shines

09/18/2020 | 06:51am EST

BENGALURU, Sept 18 (Reuters) - Indian shares gave up early gains to end lower on Friday as banking stocks fell in afternoon trading, with HDFC Bank closing at a month's low, although a jump in pharma stocks capped losses on the Nifty.

The blue-chip NSE Nifty 50 index closed 0.1% lower at 11,504.95, while the benchmark S&P BSE Sensex, which has fewer pharma components, ended down 0.34% at 38,845.82.

The Nifty ended the week 0.4% higher, while the Sensex closed a tad lower.

The Nifty Bank Index finished 1.3% lower at its worst closing level in a month, capping its third straight week of losses, dragged by a 2.4% slide in top private-sector lender HDFC Bank.

The Nifty Pharma index clocked its best day since Aug. 10, closing up 5%, as drugmaker Dr.Reddy's Laboratories Ltd added 10.5% to close at a record high.

The pharmaceutical firm settled a patent litigation with U.S. drugmaker Bristol-Myers Squibb Co over the cancer treatment Revlimid, prompting analyst upgrades to its stock.

Drugmakers Lupin Ltd and Cipla Ltd jumped 4.7% and 7.3%, respectively, after U.S.-listed Perrigo Company Plc issued a U.S. nationwide recall of its albuterol sulfate inhalation aerosol product due to complaints of clogging issues.

Cipla and Lupin have their own versions of the aerosol product approved by the U.S. FDA.

Investor sentiment in broader markets was also tepid on worries over a resurgence in coronavirus cases and disappointment that central banks merely affirmed their monetary support this week, without promising new stimulus. (Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Ramakrishnan M.)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
CIPLA LIMITED 0.96% 738.7 Delayed Quote.53.00%
DR. REDDY'S LABORATORIES LIMITED 1.92% 4898.8 End-of-day quote.70.27%
HDFC BANK LIMITED 1.70% 1426.65 End-of-day quote.12.15%
LUPIN LIMITED 0.55% 899.45 End-of-day quote.17.59%
NIFTY 50 1.00% 12987 Delayed Quote.5.67%
NIFTY BANK -1.82% 29549.75 Delayed Quote.-9.22%
SENSEX 30 0.98% 44259.74 Real-time Quote.7.92%
All news about HDFC BANK LIMITED
05:39aIndian shares jump as metals, financials gain
RE
11/23HDFC BANK : Disclosure under Reg. 30 of SEBI LODR
PU
11/16HDFC BANK : Schedule of analyst and investor meet
PU
11/05Indian banks see revival in loan growth but concerns linger
RE
11/03HDFC BANK : Notice of Postal Ballot
PU
11/01MOVES-Carlyle appoints top Indian banker Puri as senior adviser
RE
10/30THE LAW OFFICES OF FRANK R. CRUZ : Reminds Investors of Looming Deadline in the ..
BU
10/30HDB DEADLINE ALERT : Bronstein, Gewirtz & Grossman, LLC Reminds HDFC Bank Limite..
BU
10/28HDFC BANK : Intimation under Reg 30 of SEBI LODR - Appointment of Director
PU
10/28HDFC BANK : Intimation under Reg 30 of SEBI LODR - Change in directorate
PU
More news
Financials
Sales 2021 884 B 11 967 M 11 967 M
Net income 2021 286 B 3 871 M 3 871 M
Net Debt 2021 - - -
P/E ratio 2021 27,6x
Yield 2021 0,67%
Capitalization 7 856 B 106 B 106 B
Capi. / Sales 2021 8,89x
Capi. / Sales 2022 7,81x
Nbr of Employees 116 971
Free-Float 83,4%
Chart HDFC BANK LIMITED
Duration : Period :
HDFC Bank Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HDFC BANK LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 1 426,65 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Sashidhar Jagdishan Chief Executive Officer & Managing Director
Shyamala Gopinath Chairman
Srinivasan Vaidyanathan Chief Financial Officer
Ramesh Lakshminarayanan Chief Information Officer
Kaizad M. Bharucha Executive Director
Sector and Competitors